MASH (metabolic dysfunction-associated steatohepatitis, the renamed NASH) is the liver disease that has emerged as the next major peptide drug indication after obesity. Both GLP-1s and dual/triple agonists have shown MASH benefit, with the mechanism question — direct hepatic effect versus weight-loss-mediated — only recently resolved.
The most cited 2026 read: a Cell Metabolism paper from Sinai Health pinned semaglutide's MASH reversal to liver sinusoidal endothelial cells (LSECs), which account for ~3% of liver cell volume but drive hepatoprotection. Mice without LSEC GLP-1 receptors saw no liver improvement despite 20% weight loss; mice without brain appetite receptors still reversed MASH. That decouples MASH benefit from weight loss for the first time.
The May 19 pre-EASL 2026 data drop from Novo Nordisk extended the ESSENCE Phase 3 program with a favorable hepatic safety analysis of semaglutide 2.4 mg, plus dedicated subgroup data in Japanese patients and women in menopause — populations historically underrepresented in MASH trials. EASL Barcelona (May 27-30) will host the plenary read-outs.
Stories here cover trial readouts, mechanism papers, and the broader liver-disease pipeline. See #liver-disease and #liver for adjacent tags.
The European Association for the Study of the Liver (EASL) Congress 2026 opens Wednesday May 27 in Barcelona with a heavy peptide-MASH slate. Novo Nordisk's ESSENCE Phase 3 program leads with liver-safety subgroup analyses (Japanese MASH cohort, women in menopause), building on the August 2025 FDA approval of semaglutide for MASH-with-fibrosis. Eli Lilly's retatrutide MASLD Phase 3 (NCT06859268) is enrolling on the 86% Phase 2 liver-fat reduction baseline. Boehringer Ingelheim survodutide SYNCHRONIZE-1 Phase 3 MASH data is expected late 2026 with positive results potentially establishing the GLP-1/glucagon dual agonist as standard of care alternative to semaglutide. MetaVia's vanoglipel (DA-1241, GPR119 agonist) Phase 2a + resmetirom combination work presented at ECO 2025 anchors the combination-MASH therapy thesis. The EASL plenaries plus the May 21 TRIUMPH-1 readout reframe MASH as a peptide-mechanism battleground rather than a single-drug indication.
Eli Lilly's retatrutide MASLD Phase 3 program (NCT06859268) continues enrollment across multiple international sites following the December 2025 Phase 2 readout that documented 86% mean liver-fat reduction at 48 weeks on 12 mg dosing. The Phase 3 trial enrolls adults with biopsy-confirmed MASH stages F2-F3 with primary endpoint at week 52 measuring MASH resolution without worsening of fibrosis. The 86% liver-fat reduction substantially exceeds the resmetirom 38-46% benchmark from the MAESTRO-NAFLD-1 reference cohort. Topline data is expected H1 2027; full results at AASLD or EASL 2027. The MASLD Phase 3 sits alongside TRIUMPH-3 (obesity + CVD) and TRIUMPH-OUTCOMES (10,000-patient cardiovascular outcomes trial reading 2027) as the second 2027 retatrutide catalyst. If positive, retatrutide files for MASH labeling alongside the obesity NDA — potentially within the same FDA submission window.
Eight days ahead of EASL Congress 2026 in Barcelona (May 27-30), Novo Nordisk released new analyses from the Phase 3 ESSENCE program showing semaglutide 2.4 mg holds a favorable hepatic safety profile across MASH subgroups, including the first dedicated Japanese MASH cohort and a women-in-menopause subset. Gastrointestinal events remained the leading adverse-event signal, with small discontinuation rates. MASH affects an estimated 250 million people globally with roughly 9 in 10 cases undiagnosed; the trial data reinforce the FDA's August 2025 MASH-with-fibrosis approval and broaden the prescribing case ahead of the EASL plenaries.
Eli Lilly's retatrutide MASLD Phase 3 trial (NCT06859268) is enrolling, building on Phase 2 data that reported up to 86% liver-fat reduction at 48 weeks with 93% of 12 mg patients reaching normal liver fat. The MASLD trial will measure histological resolution of steatohepatitis without worsening fibrosis — the endpoint that drives FDA approval in the indication. The trial sits within the broader TRIUMPH program of seven Phase 3 retatrutide readouts due in 2026, after TRIUMPH-4 (28.7% mean weight loss with knee-osteoarthritis pain reduction) and TRANSCEND T2D1 (A1c down 1.7–2.0 pts in T2D). MASLD remains a regulatory test for incretins after Boehringer's survodutide LIVERAGE Phase 3 program.
Following the April 28 SYNCHRONIZE-1 obesity topline (16.6% weight loss at 76 weeks), Boehringer Ingelheim and Zealand Pharma confirmed that survodutide — their dual GLP-1/glucagon agonist — has two global Phase 3 MASH trials underway: LIVERAGE in adults with MASH and fibrosis stages F2 or F3, and LIVERAGE-Cirrhosis in compensated MASH cirrhosis. The Phase 3 program follows Phase 2 data showing 83% of MASH patients achieved histological improvement at 48 weeks. The MASH track positions survodutide alongside tirzepatide's SYNERGY-NASH and broader Lilly Phase 3 activity in the metabolic-liver-disease space, with full SYNCHRONIZE-1 data slated for ADA 2026 in June.
Researchers at Toronto's Sinai Health published in Cell Metabolism that semaglutide acts directly on liver sinusoidal endothelial cells (LSECs) to reverse MASH independently of weight loss. Although LSECs account for only ~3% of liver cell volume, they are the key driver of hepatoprotection. Semaglutide reversed MASH in mice lacking brain appetite receptors, while mice lacking LSEC receptors saw no liver improvement despite losing 20% body weight.
GLP-1 RAs, particularly semaglutide, are showing robust clinical data for liver disease with significant rates of disease resolution and improvement in liver fibrosis.
The FDA granted breakthrough therapy designation to survodutide, a dual glucagon/GLP-1 receptor agonist by Boehringer Ingelheim, for treating adults with MASH.